| Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript |
Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference Call Participants Kallum Titchmarsh - Morgan Stanley Marie Thibault - BTIG Anthony Petrone - Mizuho Securities Michael Polark - Wolfe Research Operator Welcome, ladies and gentlemen, to Embecta Corp.'s fiscal second quarter 2025 earnings conference call. At this time, all participants have been placed in a listen-only mode. |
seekingalpha.com |
2025-05-09 17:39:46 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Tops Q2 Earnings Estimates |
Embecta Corp. (EMBC) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.67 per share a year ago. |
zacks.com |
2025-05-09 12:40:40 |
Czytaj oryginał (ang.) |
| Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results |
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. |
globenewswire.com |
2025-05-09 10:30:00 |
Czytaj oryginał (ang.) |
| embecta Announces Quarterly Cash Dividend |
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. |
globenewswire.com |
2025-05-09 10:00:00 |
Czytaj oryginał (ang.) |
| Embecta to host Analyst and Investor Day on May 22, 2025 |
PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City. |
globenewswire.com |
2025-04-28 11:30:00 |
Czytaj oryginał (ang.) |
| embecta to Report Fiscal Second Quarter 2025 Financial Results |
PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. |
globenewswire.com |
2025-04-21 21:00:00 |
Czytaj oryginał (ang.) |
| Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations |
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings. |
globenewswire.com |
2025-04-01 12:05:00 |
Czytaj oryginał (ang.) |
| Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour |
Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent use of EMBC's product. |
seekingalpha.com |
2025-02-28 04:17:38 |
Czytaj oryginał (ang.) |
| embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference |
PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET. |
globenewswire.com |
2025-02-18 19:00:00 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Q1 2025 Earnings Call Transcript |
Embecta Corp. (NASDAQ:EMBC ) Q1 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - President & Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Kallum Titchmarsh - Morgan Stanley Ryan Schiller - Wolfe Research Operator Good day, and thank you for standing by. Welcome, ladies and gentlemen, to the Embecta Fiscal First Quarter 2025 Earnings Conference Call. |
seekingalpha.com |
2025-02-06 15:55:18 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Tops Q1 Earnings and Revenue Estimates |
Embecta Corp. (EMBC) came out with quarterly earnings of $0.65 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.61 per share a year ago. |
zacks.com |
2025-02-06 10:45:40 |
Czytaj oryginał (ang.) |
| Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results |
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2024. |
globenewswire.com |
2025-02-06 08:30:00 |
Czytaj oryginał (ang.) |
| embecta Announces Quarterly Cash Dividend |
PARSIPPANY, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 14, 2025 to stockholders of record at the close of business on February 28, 2025. |
globenewswire.com |
2025-02-06 08:00:00 |
Czytaj oryginał (ang.) |
| embecta to Report Fiscal First Quarter 2025 Financial Results |
PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. |
globenewswire.com |
2025-01-23 19:00:00 |
Czytaj oryginał (ang.) |
| The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC |
Doximity, Omnicell, Embecta, Cencora and EDOC are included in this Analyst Blog. |
zacks.com |
2025-01-23 06:45:27 |
Czytaj oryginał (ang.) |
| 4 MedTech Stocks Poised to Thrive Under Second Trump Presidency |
Four MedTech stocks that are set to benefit from Trump 2.0 are DOCS, OMCL, EMBC and COR. |
zacks.com |
2025-01-22 14:56:10 |
Czytaj oryginał (ang.) |
| 3 Stocks Trading Near 52-Week High With Room to Rise Further |
Investors target stocks that have been on a bullish run lately. Stocks like EMBC, NFG and REVG are seeing price strength and the momentum is likely to continue. |
zacks.com |
2025-01-06 11:36:17 |
Czytaj oryginał (ang.) |
| 3 Medical Services Stocks to Buy to Counter Labor Shortage Woes |
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. DOCS, BTSG and EMBC are set to gain the most. |
zacks.com |
2025-01-03 06:31:11 |
Czytaj oryginał (ang.) |
| 4 Best-Bargain PEG Stocks That Value Investors Love |
Here are four stocks that fit our screening criteria. These are GAP, EMBC, BLBD and ZIM. |
zacks.com |
2024-12-23 11:51:39 |
Czytaj oryginał (ang.) |
| embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference |
PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. |
globenewswire.com |
2024-12-19 19:00:00 |
Czytaj oryginał (ang.) |
| New Initiatives Expected To Make Embecta More Profitable |
Embecta Corp.'s Q4 results showed significant net income and EPS growth as well as profitability plans, and drove up the share price. The company announced a restructuring plan to streamline operations, reduce costs by up to $65 million annually, and discontinue its insulin patch pump program. Embecta aims to strengthen its core business, expand its GLP-1 therapies portfolio, and reduce debt, positioning it for profitable growth in fiscal 2025. |
seekingalpha.com |
2024-12-04 10:30:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 2nd |
EMBC, TOST, MNDY, NTRS and MANU have been added to the Zacks Rank #1 (Strong Buy) List on December 2, 2024. |
zacks.com |
2024-12-02 09:56:07 |
Czytaj oryginał (ang.) |
| Best Value Stocks to Buy for December 2nd |
EMBC, BLBD and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 2, 2024. |
zacks.com |
2024-12-02 07:21:08 |
Czytaj oryginał (ang.) |
| Best Income Stocks to Buy for December 2nd |
CTBI and EMBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on December 2, 2024. |
zacks.com |
2024-12-02 07:16:08 |
Czytaj oryginał (ang.) |
| Overlooked Stock: EMBC |
Bad news is good news? Appears to be the case for medical device company Embecta (EMBC) as shares soared after it stopped its insulin patch pump program. |
youtube.com |
2024-11-27 18:38:18 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Q4 2024 Earnings Call Transcript |
Embecta Corp. (NASDAQ:EMBC ) Q4 2024 Earnings Conference Call November 26, 2024 8:00 AM ET Company Participants Pravesh Khandelwal - VP of IR Dev Kurdikar - President and CEO Jake Elguicze - CFO Conference Call Participants Marie Thibault - BTIG Operator Good day, and welcome to the Embecta Fourth Quarter of Fiscal Year 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. |
seekingalpha.com |
2024-11-26 16:04:17 |
Czytaj oryginał (ang.) |
| Becton Dickinson Spinoff Embecta Stops Insulin Patch Pump Program, Plans Restructuring, Stock Jumps |
On Tuesday, Embecta Corp EMBC posted the fourth-quarter adjusted EPS of 45 cents, beating the consensus of 36 cents and down from 59 cents reported a year ago. |
benzinga.com |
2024-11-26 15:15:05 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Tops Q4 Earnings and Revenue Estimates |
Embecta Corp. (EMBC) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.40 per share. This compares to earnings of $0.59 per share a year ago. |
zacks.com |
2024-11-26 10:41:17 |
Czytaj oryginał (ang.) |
| Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs |
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three- and twelve-month periods ended September 30, 2024. |
globenewswire.com |
2024-11-26 08:30:00 |
Czytaj oryginał (ang.) |
| embecta Announces Quarterly Cash Dividend |
PARSIPPANY, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on December 18, 2024 to stockholders of record at the close of business on December 6, 2024. |
globenewswire.com |
2024-11-26 08:00:00 |
Czytaj oryginał (ang.) |
| UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results |
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Tuesday, November 26, 2024. |
globenewswire.com |
2024-11-12 19:31:00 |
Czytaj oryginał (ang.) |
| embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results |
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal fourth quarter and full year 2024 financial results, and provide an operational update, including preliminary fiscal year 2025 financial guidance, at 8:00 a.m. Eastern Time (ET) on Thursday, November 26, 2024. |
globenewswire.com |
2024-11-12 19:00:00 |
Czytaj oryginał (ang.) |
| embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell |
embecta will be joined by diabetes advocacy groups to ring the Nasdaq Closing Bell today in recognition of National Diabetes Awareness Month in November. |
globenewswire.com |
2024-11-07 08:30:00 |
Czytaj oryginał (ang.) |
| Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump |
EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes. |
zacks.com |
2024-09-04 13:26:38 |
Czytaj oryginał (ang.) |
| embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes |
embecta has received 510(k) clearance from the FDA for its proprietary disposable insulin delivery system, a patch pump with a 300-unit insulin reservoir. |
globenewswire.com |
2024-09-03 10:30:00 |
Czytaj oryginał (ang.) |
| embecta to Participate in Investor Events |
PARSIPPANY, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that management will participate in the following investor events: |
globenewswire.com |
2024-08-22 21:00:00 |
Czytaj oryginał (ang.) |
| Embecta Corp. (EMBC) Just Overtook the 200-Day Moving Average |
From a technical perspective, Embecta Corp. (EMBC) is looking like an interesting pick, as it just reached a key level of support. EMBC recently overtook the 200-day moving average, and this suggests a long-term bullish trend. |
zacks.com |
2024-08-12 14:30:46 |
Czytaj oryginał (ang.) |